„Biosimilar prices in the US are already at European level“
Interview with goingpublic (in German only)
Dr. Stefan Glombitza
Chief Executive Officer (CEO)
Formycon AG
In an interview with goingpublic, Dr. Stefan Glombitza, Chief Executive Officer of Formycon AG, talks about Formycon`s future strategy for product commercialization and the market environment for biosimilars in the US.
The complete interview can be read here:
„Biosimilarpreise in den USA sind bereits auf europäischem Niveau“ | GoingPublic.de
